Hadrian Secures $360 Million Credit Facility to Expand U.S. Manufacturing Network


Opening of Hadrian’s factory in Cherokee, AL.

Hadrian has closed a $360 million revolving credit facility to finance additional manufacturing infrastructure, machinery and related hardware as the advanced manufacturing company expands production capacity for U.S. defense and aerospace customers.

The financing follows Hadrian’s recently announced $1.37 billion Series D funding round, which valued the company at $7.87 billion. Together, the equity raise and new credit facility provide additional capital for a manufacturing buildout that now spans four facilities totaling just under 3 million square feet, with more sites under development.

Morgan Stanley Senior Funding Inc. served as lead left arranger and bookrunner for the revolving facility. Western Alliance Bank, J.P. Morgan, First Citizens Bank, Customers Bank, HSBC Ventures USA Inc., Axos Bank and Texas Capital Securities also served as joint lead arrangers and bookrunners.

Hadrian plans to use the credit facility to continue investing in the physical infrastructure required to scale its manufacturing model. Unlike funding directed primarily toward software development or corporate expansion, the facility is intended to support capital-intensive assets including production equipment and factory hardware.

That capacity is central to Hadrian’s strategy of building highly automated U.S. factories that combine process engineering, artificial intelligence and robotics. The company is targeting defense and aerospace manufacturing, where scaling production requires not only factory space but also specialized machinery, production systems and repeatable processes capable of meeting customer requirements.

“This facility’s closing represents a key next step in Hadrian’s growth trajectory,” founder and CEO Chris Power said. He added that the financing will support the company’s efforts to build additional U.S. industrial capacity and create manufacturing jobs.

Hadrian currently operates two facilities in Torrance, California, along with newly launched sites in Arizona and Alabama. Its four facilities collectively cover just under 3 million square feet, and the company has additional locations in development across the country.

The geographic expansion reflects the infrastructure requirements behind Hadrian’s effort to increase domestic production for space and defense programs. Building a larger manufacturing network requires coordinating factory construction, machinery installation, automation systems and production ramp-up while maintaining consistent processes across sites.

Hadrian’s model is designed to use automation to address those execution challenges. The company combines robotics and AI with manufacturing process engineering, seeking to increase production capacity while giving workers tools to manage more automated factory workflows.

The $360 million revolving structure also provides a different source of capital from Hadrian’s Series D equity financing. A revolving credit facility can give a company access to capital as spending requirements emerge, providing flexibility as equipment purchases and factory investments progress across multiple locations.

The new financing arrives one week after Hadrian announced the $1.37 billion Series D. The company did not provide a breakdown of how the equity financing and revolving facility will be allocated among individual factories or equipment programs.

Hadrian’s expansion is focused on the manufacturing infrastructure behind defense and aerospace supply chains, where increasing output can involve significant capital spending before additional production comes online. Factory footprints must be developed and equipped, manufacturing processes validated and capacity coordinated with customer programs.

The company ultimately aims to enable space and defense manufacturers to produce complete programs at greater scale in the United States. Its growing network of factories provides the physical foundation for that strategy, while automation is intended to improve how production capacity can be deployed and replicated across facilities.

Kirkland & Ellis served as legal counsel to Hadrian on the revolving credit transaction.

With its latest debt facility and Series D financing completed in close succession, Hadrian has added substantial capital for the next stage of its U.S. factory buildout, shifting the focus toward deploying machinery, commissioning infrastructure and translating its expanded footprint into production capacity for aerospace and defense customers.

Free Training

Source link

Octapharma To Build $1.5 Billion Critical Care Manufacturing Facility In South Carolina


Octapharma plans to invest $1.5 billion in its first U.S.-based manufacturing and production facility, creating approximately 1,500 full-time jobs in Rock Hill, South Carolina.

The 50-acre campus will be developed at Palmetto Research Park and is expected to become one of the largest private biomedical investments in South Carolina’s history.

The facility will produce plasma-derived therapies from Octapharma’s portfolio, establishing domestic manufacturing capabilities for medicines currently supported by the company’s international production network.

Octapharma also plans to manufacture bleeding management and trauma care products used for national security and emergency preparedness purposes.

The project is intended to reduce dependence on overseas pharmaceutical supply chains while bringing production closer to the plasma donated in the United States and the American patients who rely on the company’s treatments.

Octapharma selected Rock Hill following a planning and zoning process conducted with Rock Hill and York County officials and in coordination with local, state and federal leaders.

The company cited South Carolina’s advanced manufacturing infrastructure, logistics network, access to deep-water ports and growing biomedical workforce as factors supporting the location decision.

Octapharma expects demand for its existing therapies and future products to increase, requiring the company to expand its manufacturing capacity.

Construction and groundbreaking details will be announced at a later date.

Headquartered in Lachen, Switzerland, Octapharma develops and manufactures human protein therapies derived from human plasma and cell lines. The company has more than 11,000 employees and serves patients in 117 countries across immunotherapy, hematology and critical care.

Octapharma currently operates five European manufacturing facilities, seven research and development sites and more than 200 plasma donation centers across the United States and Europe.

KEY QUOTES:

“We expect significant future growth, driven by our existing life-saving therapies and a strong pipeline of new products. Our manufacturing capacity must evolve to support this ambition, and our U.S. manufacturing facility will be an important milestone. From a U.S. national security perspective, having the ability to produce and supply our therapies domestically is invaluable.”

Wolfgang Marguerre, CEO and Chairman of Octapharma

“We have built a significant presence in the U.S. over the last 20 years through our commercial capabilities, alongside our extensive network of plasma donation centers. As the demand in the U.S. for our portfolio of products continues to grow, the new U.S. manufacturing site will bring production of our FDA-approved therapies closer to both the plasma donated in the U.S. and to the patients who rely on them.”

Tobias Marguerre, Deputy Chairman of Octapharma

“Octapharma appreciates the good-faith work of every elected official and staff member in York County and Rock Hill who helped bring this to fruition. We also want to thank Governor McMaster and South Carolina’s federal and state delegation for their support in welcoming Octapharma to the Palmetto State.”

“South Carolina’s talented workforce, strong life sciences ecosystem and pro-business environment made it clear this was the right home for our first U.S. manufacturing facility.”

Flemming Nielsen, President of Octapharma USA

Thank you for visiting Pulse 2.0. We work hard every day to bring leaders and decision makers like you the latest intelligence on business, finance, capital markets, deal flow, law, tech, and AI. Click here to subscribe to the Pulse 2.0 Newsletter.

Free Training

Source link

Octapharma To Build $1.5 Billion State-Of-The-Art Critical Care Manufacturing Facility In Rock Hill, SC


Octapharma, the largest privately owned and independent plasma fractionator in the world, has formally announced plans to establish its first-ever United States-based manufacturing and production site at the Palmetto Research Park in Rock Hill, South Carolina. The $1.5 billion project is expected to bring 1,500 full-time jobs to South Carolina, making it one of the largest private biomedical investments in the state’s history.

Once operations commence, the facility will produce critical, life-saving medicines from Octapharma’s portfolio of plasma-derived therapies, strengthening the domestic biomedical supply chain while complementing the company’s global manufacturing capabilities. The Rock Hill site will also produce bleeding management and trauma care products for national security and emergency preparedness needs. The announcement follows a thorough planning and zoning process coordinated with officials from Rock Hill and York County, alongside local, state, and federal leaders.

Rock Hill was selected for its proven infrastructure for advanced manufacturing, access to deep-water ports, and proximity to major logistics networks. South Carolina’s pipeline of biomedical and life sciences talent, supported by technical colleges and universities, is expected to provide the workforce needed to support the facility. Octapharma has built a significant US presence over the past 20 years through its commercial capabilities and extensive network of plasma donation centers, and the new site is intended to bring production of its FDA-approved therapies closer to both the plasma donated in the US and the patients who rely on them.

Octapharma is headquartered in Lachen, Switzerland, with more than 11,000 employees serving patients in 117 countries across Immunotherapy, Hematology, and Critical Care. The company operates 190 plasma donation centers across the United States and seven R&D sites and five manufacturing facilities in Europe. More details regarding a groundbreaking ceremony and construction timeline will be released at a later date.

KEY QUOTES:

“We expect significant future growth, driven by our existing life-saving therapies and a strong pipeline of new products. Our manufacturing capacity must evolve to support this ambition, and our US manufacturing facility will be an important milestone. From a US national security perspective, having the ability to produce and supply our therapies domestically is invaluable.”

Wolfgang Marguerre, CEO and Chairman, Octapharma

“We have built a significant presence in the US over the last 20 years through our commercial capabilities, alongside our extensive network of plasma donation centres. As the demand in the US for our portfolio of products continues to grow, the new US manufacturing site will bring production of our FDA-approved therapies closer to both the plasma donated in the US, and to the patients who rely on them.”

Tobias Marguerre, Deputy Chairman, Octapharma

“Octapharma appreciates the good-faith work of every elected official and staff member in York County and Rock Hill who helped bring this to fruition. South Carolina’s talented workforce, strong life sciences ecosystem, and pro-business environment made it clear this was the right home for our first US manufacturing facility.”

Flemming Nielsen, President, Octapharma USA

Thank you for visiting Pulse 2.0. We work hard every day to bring leaders and decision makers like you the latest intelligence on business, finance, capital markets, deal flow, law, tech, and AI. Click here to subscribe to the Pulse 2.0 Newsletter.

Free Training

Source link

Octapharma to build $1.5 billion state-of-the-art critical care manufacturing facility in Rock Hill, SC


New 50-acre campus will be one of the largest private biomedical investments in state’s history, bringing 1,500 jobs to South Carolina

Manufacturing facility will establish domestic production of Octapharma’s plasma-based therapies and products of national security concern, reducing dependency on overseas supply chains

PARAMUS, N.J., July 29, 2026 /PRNewswire/ — Octapharma, the largest privately owned and independent plasma fractionator in the world, has formally announced plans to establish its first-ever United States-based manufacturing and production site at the Palmetto Research Park in Rock Hill, South Carolina. The $1.5 billion project is expected to bring 1,500 full-time jobs to South Carolina, making this one of the largest private biomedical investments in the state’s history.  

Once operations commence, this facility will produce critical, life-saving medicines from Octapharma’s portfolio of plasma-derived therapies, strengthening the domestic biomedical supply chain while also complementing the company’s global manufacturing capabilities. Octapharma’s Rock Hill site will also produce bleeding management and trauma care products for national security and emergency preparedness needs.

Today’s announcement follows a thorough planning and zoning process coordinated with officials from Rock Hill and York County, and close partnership with local, state and federal leaders. 

“We expect significant future growth, driven by our existing life-saving therapies and a strong pipeline of new products,” said Wolfgang Marguerre, CEO and Chairman, Octapharma. “Our manufacturing capacity must evolve to support this ambition, and our US manufacturing facility will be an important milestone. From a US national security perspective, having the ability to produce and supply our therapies domestically is invaluable.”

“We have built a significant presence in the US over the last 20 years through our commercial capabilities, alongside our extensive network of plasma donation centres,” said Tobias Marguerre, Deputy Chairman, Octapharma. “As the demand in the US for our portfolio of products continues to grow, the new US manufacturing site will bring production of our FDA-approved therapies closer to both the plasma donated in the US, and to the patients who rely on them.”

Octapharma’s Commitment to Rock Hill
South Carolina’s leadership and Octapharma share a commitment to biomedical innovation, domestic supply chain resilience, and long-term economic investment in the surrounding community. 

With its proven infrastructure for advanced manufacturing, access to deep-water ports and proximity to major logistics networks, Rock Hill was selected as an ideal location for Octapharma’s first US facility. Additionally, South Carolina’s strong pipeline of biomedical and life sciences talent, supported by top-tier technical colleges and universities, will provide the workforce needed to support clean, efficient biopharmaceutical manufacturing at scale.

“Octapharma appreciates the good-faith work of every elected official and staff member in York County and Rock Hill who helped bring this to fruition,” said Flemming Nielsen, President, Octapharma USA. “We also want to thank Governor McMaster and South Carolina’s federal and state delegation for their support in welcoming Octapharma to the Palmetto State. South Carolina’s talented workforce, strong life sciences ecosystem, and pro-business environment made it clear this was the right home for our first US manufacturing facility.” 

More details regarding a groundbreaking ceremony and construction timeline will be released at a later date.  

To view the full release from the South Carolina Department of Commerce, please click here.  

About Octapharma
Octapharma is one of the world’s largest human protein manufacturers, developing and producing therapies from human plasma and human cell lines. Headquartered in Lachen, Switzerland, Octapharma has over 11,000 employees and serves patients in 117 countries across Immunotherapy, Hematology, and Critical Care. Octapharma has 190 plasma donation centers across the United States 

With seven R&D sites, five manufacturing facilities in Europe, and more than 200 plasma donation centers in the US and Europe, Octapharma has delivered trusted therapies for over 40 years. The company is committed to improving lives through innovation, quality, and a deep focus on patient care and clinical partnership. To learn more please visit www.octapharma.com

Media Contact:
Michael Steier
[email protected]
+1 (551) 410-7797

SOURCE Octapharma

Free Training

Source link

Boresight (ASX:BST) Expands US Manufacturing Footprint with New Huntsville Facility


Highlights

  • Boresight has leased a new 812-square-metre manufacturing facility in Huntsville, Alabama.
  • The new site is approximately 15 times larger than the company’s existing US facility.
  • Production of the BQ-400 aerial target drone will transition during August and September 2026.
  • The expansion is intended to support increasing demand from US defence customers.

Boresight Limited (ASX:BST) remained on investors’ radar after its shares traded higher on 23 July 2026. While no confirmed closing price was available, recent market attention has focused on the company’s expansion of its United States manufacturing operations through a substantially larger production facility in Huntsville, Alabama.

The move marks another operational milestone as Boresight continues increasing manufacturing capacity for its aerial target drone business.

Manufacturing Capacity Set to Increase

Boresight has leased an 812-square-metre manufacturing facility in Huntsville, Alabama, which is approximately 15 times larger than its existing US premises.

The company has already taken occupancy under an initial three-year lease, with options to extend.

Production is expected to transition to the new facility during August and September 2026, while the site fit-out is scheduled for completion later in September.

The larger facility is expected to improve production capacity and support growing customer demand in the United States.

Focus Remains on Aerial Target Drones

The Huntsville facility will initially manufacture the company’s BQ-400 aerial target drone, with a stated production objective of more than 5,000 units annually.

Over time, the company expects the facility to support production of additional products, including the BQ-750 Block 2 platform.

Boresight develops low-cost aerial target drones used for military training, allowing defence organisations to simulate airborne threats during exercises.

The company also provides supporting control systems and mission-planning software for coordinated drone operations.

US Expansion Supports Defence Strategy

Huntsville is recognised as a major US defence and aerospace hub.

By expanding its manufacturing presence in Alabama, Boresight expects to improve responsiveness to US customers while reducing delivery times and freight costs.

The company will retain its Australian facility in Fyshwick, which will continue supporting product development, innovation and production for non-US markets.

The US expansion therefore complements, rather than replaces, the company’s Australian operations.

Production Growth Remains the Primary Focus

Boresight continues investing in manufacturing capability as it expands within the defence technology sector.

Future updates are expected to provide additional information on production ramp-up, customer orders and operational performance following the transition to the larger facility.

Although the company’s shares traded higher on 23 July 2026, no verified evidence directly linked the intraday share-price movement to a specific corporate announcement.

What Investors May Watch

Investors may monitor completion of the Huntsville facility transition, production volumes, customer contracts, manufacturing capacity, defence sector demand and future operational updates.

Risks

Boresight operates within the defence technology sector and remains exposed to customer demand, manufacturing execution, government procurement cycles, contract timing, supply chain factors and broader defence spending trends.

Free Training

Source link

Foodservice Packaging Supplier Detpak Opens U.S. Manufacturing Facility


SPARTANBURG, S.C. — Global packaging supplier Detpak has announced the opening of its new manufacturing facility in Spartanburg, South Carolina, strengthening its ability to support major Quick Service Restaurant (QSR) customers with locally produced, paper-based packaging solutions.

Detpak’s new U.S. manufacturing facility in Spartanburg, South Carolina, strengthens local manufacturing capabilities and expands support for Quick Service Restaurant (QSR), foodservice, Fast-Moving Consumer Goods (FMCG), and retail customers across North America.

Detpak, a Detmold Group company headquartered in Australia, is a trusted packaging partner to some of the world’s largest and most recognizable QSR, foodservice, FMCG and retail brands, with experience supplying global customers such as McDonald’s, KFC, Starbucks, and Wendy’s. The company has supported customers in the United States for more than two decades, operates in 45 countries, and owns manufacturing facilities in eight countries.

The new US manufacturing facility marks a significant step in Detpak’s global expansion and reinforces its long-term commitment to the North American market. By combining its global expertise with local manufacturing capability, Detpak will be better positioned to support US customers with improved supply chain reliability, reduced lead times and greater operational flexibility.

“As we continue to grow our global footprint, opening our own manufacturing facility in the United States is a key milestone for our business,” CEO Sascha Detmold Cox said.

“It allows us to better support our customers with locally manufactured products and reinforces our commitment to the U.S. market where we have been supplying customers from our international plants for over 20 years. We’re focused on building long-term partnerships and delivering the same level of service, innovation and reliability that our customers experience globally.”

“We’re proud to be investing in the Spartanburg community and creating new employment opportunities in South Carolina.” Ms. Detmold Cox said.

Initially employing more than 50 people from the local community, the multi-million-dollar facility, spanning 175,000 square feet, is currently undergoing equipment commissioning, with full production commencing in August.

About Detpak and the Detmold Group

Wholly owned by the Detmold Group, Detpak designs, manufactures and supplies the Quick Service Restaurant (QSR), Fast-Moving Consumer Goods (FMCG), grocery and food services industry with world-class sustainable paper and cardboard packaging solutions. Detpak delivers a level of service and care that exceeds standards, with the understanding and operational integrity of a family-owned business. Many of the paper and board packaging products used in the fast-food industry, including from Starbucks, Uber Eats, Burger King and Krispy Kreme are supplied by Detpak.

With headquarters in Australia, the Detmold Group is a 78-year-old, family-owned and operated business, supplying packaging to the world’s largest and most iconic food and retail brands. Detpak serves a range of markets, including fresh produce, QSR, foodservice, Fast-Moving Consumer Goods (FMCG) and grocery and convenience.

Free Training

Source link

DETPAK OPENS U.S. MANUFACTURING FACILITY IN SPARTANBURG, SOUTH CAROLINA


SPARTANBURG, S.C., July 20, 2026 /PRNewswire/ — Global packaging supplier Detpak today announced the opening of its new manufacturing facility in Spartanburg, South Carolina, strengthening its ability to support major Quick Service Restaurant (QSR) customers with locally produced, paper-based packaging solutions.

Detpak's new U.S. manufacturing facility in Spartanburg, South Carolina, strengthens local manufacturing capabilities and expands support for Quick Service Restaurant (QSR), foodservice, FMCG, and retail customers across North America. Learn more: https://www.detpak.com Detpak’s new U.S. manufacturing facility in Spartanburg, South Carolina, strengthens local manufacturing capabilities and expands support for Quick Service Restaurant (QSR), foodservice, FMCG, and retail customers across North America. Learn more: https://www.detpak.com

Detpak, a Detmold Group company headquartered in Australia, is a trusted packaging partner to some of the world’s largest and most recognizable QSR, foodservice, FMCG and retail brands, with experience supplying global customers such as McDonald’s, KFC, Starbucks, and Wendy’s. The company has supported customers in the United States for more than two decades, operates in 45 countries, and owns manufacturing facilities in eight countries.

The new US manufacturing facility marks a significant step in Detpak’s global expansion and reinforces its long-term commitment to the North American market. By combining its global expertise with local manufacturing capability, Detpak will be better positioned to support US customers with improved supply chain reliability, reduced lead times and greater operational flexibility.

“As we continue to grow our global footprint, opening our own manufacturing facility in the United States is a key milestone for our business,” CEO Sascha Detmold Cox said.

“It allows us to better support our customers with locally manufactured products and reinforces our commitment to the U.S. market where we have been supplying customers from our international plants for over 20 years. We’re focused on building long-term partnerships and delivering the same level of service, innovation and reliability that our customers experience globally.”

“We’re proud to be investing in the Spartanburg community and creating new employment opportunities in South Carolina.” Ms. Detmold Cox said.

Initially employing more than 50 people from the local community, the multi-million-dollar facility, spanning 175,000 square feet, is currently undergoing equipment commissioning, with full production commencing in August.

About Detpak and the Detmold Group

Wholly owned by the Detmold Group, Detpak designs, manufactures and supplies the Quick Service Restaurant (QSR), Fast-Moving Consumer Goods (FMCG), grocery and food services industry with world-class sustainable paper and cardboard packaging solutions. Detpak delivers a level of service and care that exceeds standards, with the understanding and operational integrity of a family-owned business. Many of the paper and board packaging products used in the fast-food industry, including from Starbucks, Uber Eats, Burger King and Krispy Kreme are supplied by Detpak.

Free Training

Source link

Global packaging company chooses Spartanburg Co. for first U.S. manufacturing facility


SPARTANBURG COUNTY, S.C. (WSPA) — Detpak USA announced Thursday morning it will establish its first U.S. manufacturing operation in Spartanburg County. The global packaging supplier’s multi-million-dollar investment is expected to create more than 50 new jobs during its initial phase.

Detpak is a global packaging supplier that supports quick-service restaurants, food service, fast-moving consumer goods and retail customers. The company is a subsidiary of Detmold Group, an Australian company known for producing premium packaging solutions.

The new production facility will be approximately 175,000 square feet, located at 2781 New Cut Road. This operation is intended to support the company’s North American market growth and will use both imported and locally sourced raw materials from existing suppliers.

The Coordinating Council for Economic Development awarded a $100,000 Set-Aside grant to Spartanburg County. This grant is designated to assist with the costs of building improvements.

Operations for Detpak USA’s new Spartanburg County facility are expected to be online in August 2026. Individuals interested in joining the Detpak team should visit the company’s careers page for more information.

Nikolette Miller is a digital reporter/content producer at 7NEWS. She joined the team in March 2022. She is a native of Spartanburg and a proud graduate of Dorman High School and Winthrop University. You can read more of her work here.

Copyright 2026 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

 For the latest news, weather, sports, and streaming video, head to WSPA 7NEWS. 

Free Training

Source link

Fulflex Acquires 300,000-Square-Foot Texas Medical Manufacturing Facility to Expand U.S. Healthcare Platform


Fulflex Acquires 300,000-Square-Foot, Fully Automated Medical Products Manufacturing Facility In Texas

Fulflex has completed the acquisition of a 300,000-square-foot medical products manufacturing facility in Jacksonville, Texas, significantly expanding its North American production capacity and reinforcing its strategy to build a larger global healthcare manufacturing platform.

Located on a 30-acre campus, the facility becomes one of Fulflex’s largest and most advanced manufacturing sites worldwide. The acquisition also brings more than 250 employees into the company, strengthening its manufacturing workforce while establishing a larger operational presence in East Texas.

The Jacksonville facility produces a broad range of medical products used by healthcare providers and patients globally. Its manufacturing capabilities include plastics injection molding, blow molding, thermoforming, extrusion, automated assembly and other advanced production technologies, enabling Fulflex to increase output while supporting customers with scalable, high-quality manufacturing solutions.

“This is an exciting day for Fulflex and for the Jacksonville community,” said Diya Garware Ibanez, Chairperson of Fulflex. “We are delighted to officially welcome the Jacksonville team into the Fulflex family. This acquisition reflects our confidence in the exceptional people, the advanced manufacturing capabilities of this facility, and the long-term future of healthcare manufacturing in East Texas. We are committed to investing in this facility, creating new opportunities for our employees, supporting our customers with world-class manufacturing, and contributing positively to the Jacksonville community for many years to come.”

The acquisition expands Fulflex’s manufacturing footprint across North America while increasing capacity in polymer processing, medical device manufacturing and automated production. The additional facility also enhances supply chain resilience by providing greater geographic diversification and production flexibility for customers operating in global healthcare markets.

The investment aligns with Fulflex’s long-term strategy of expanding through advanced manufacturing assets that strengthen operational scale and support growing demand for medical products. The company said it plans to build on the Jacksonville facility’s existing capabilities through continued investments in manufacturing technology, quality systems, operational excellence and workforce development.

“Every acquisition begins and ends with people,” Garware Ibanez said. “The dedication, experience, and commitment of the Jacksonville employees are the foundation of this facility’s success. We are honored that so many talented people have chosen to continue this journey with us, and we look forward to building an organization where our employees can grow, our customers can succeed, and our community can thrive.”

The transition was formally marked with a community event attended by employees, customers, local officials and business leaders, underscoring the company’s commitment to maintaining the facility’s operations while investing in its long-term growth.

Following the acquisition, Fulflex operates 14 locations worldwide, including four manufacturing facilities in the United States, one manufacturing facility in the Dominican Republic, two manufacturing facilities in India, and seven sales offices and distribution centers across eight countries. The company’s global network serves customers in more than 85 countries, providing medical products and engineered polymer solutions for applications spanning medical devices, patient care, rehabilitation and personal protective equipment.

By expanding its U.S. manufacturing base with one of its largest production facilities, Fulflex is positioning itself to support increasing demand from healthcare customers while strengthening its role as a global contract manufacturing partner with enhanced capacity, operational flexibility and regional supply chain capabilities.

Free Training

Source link

Supreme Group establishes first U.S. manufacturing facility to strengthen nonwoven materials business


By K. Gopalakrishnan

$25.8 Million Investment in North Carolina to Drive Innovation, Application Development and Customer Collaboration

Supreme Group, one of India’s leading manufacturers of advanced nonwoven materials and engineered textile solutions, has announced a major strategic investment in the United States through its subsidiary, Supreme Nonwoven Inc. The company will invest approximately US$25.8 million to establish its first manufacturing facility in the U.S., marking a significant milestone in its global expansion journey.

Located in Lexington, North Carolina, the new facility will serve as an integrated hub for application engineering, product development, technical collaboration, and manufacturing, enabling the company to strengthen its presence in North America and work more closely with customers across a wide range of industrial and automotive applications.

Amit Kavrie, Managing Director, Supreme Group

The investment underscores Supreme Group’s long-term commitment to the U.S. market and reflects its strategy of bringing advanced material technologies closer to customers while enhancing responsiveness, innovation, and localized manufacturing capabilities.

Building a Stronger Presence in High-Performance Nonwovens

Over nearly four decades, Supreme Group has established a strong reputation in the development and manufacture of advanced nonwoven materials serving diverse sectors including automotive, apparel, filtration, and industrial applications. The company has built a broad technology platform that enables it to transform specialized materials into value-added solutions tailored to customer requirements.

The new manufacturing facility, spanning more than 200,000 square feet, will significantly enhance the company’s ability to collaborate with customers in North America on customized material solutions. By integrating product development, application engineering, and manufacturing under one roof, Supreme aims to accelerate innovation cycles and improve speed-to-market for new products.

According to the company, the facility will play a critical role in strengthening its ability to develop, test, and refine materials closer to their end-use environments.

“Our decision to establish this facility in North Carolina reflects a long-term commitment to serving the U.S. market with locally manufactured nonwoven materials,” said Amit Kavrie, Managing Director, Supreme Group. “We see this as an important step in bringing our material technologies and development capabilities closer to customers in the region while building a foundation for long-term growth.”

Focus on Application Development and Customer-Centric Innovation

A distinguishing feature of the investment is its emphasis on technical collaboration and application-focused innovation. Rather than serving solely as a production facility, the site is being designed as a center where customers and partners can work closely with Supreme’s technical teams to develop customized material solutions for evolving market requirements.

The company believes that proximity to customers will enable a deeper understanding of application challenges while supporting more efficient product trials, validation processes, and commercialization efforts.

In its announcement, Supreme noted that the facility will focus on enhancing performance, consistency, and application relevance across its product portfolio. The local presence is expected to improve alignment with customer requirements and ensure more consistent execution across projects.

“Over time, it will strengthen our ability to develop and trial materials closer to their end use, with a focus on performance, consistency and application relevance,” the company stated.

The investment also reflects Supreme’s intention to establish a stable and scalable manufacturing platform that can evolve in line with future market demand.

Supporting Automotive and Industrial Growth Opportunities

The new U.S. facility is expected to play a key role in serving high-growth sectors such as automotive and industrial manufacturing, where demand for advanced nonwoven materials continues to increase.

As automotive manufacturers seek lighter, more sustainable, and performance-driven material solutions, nonwovens are becoming increasingly important across interior applications, acoustic systems, filtration, insulation, and engineered components. Similarly, industrial markets continue to require specialized nonwoven solutions that combine durability, functionality, and cost efficiency.

By locating closer to major customer bases, Supreme aims to strengthen technical support, improve responsiveness, and create stronger partnerships with OEMs, Tier suppliers, and industrial manufacturers throughout North America.

“Lexington offers us a strong base from which to support customers with responsiveness, technical collaboration, and reliable execution,” said Manoj Swain, Director of International Operations, Supreme Group. “As we build this operation, our focus will be on creating the right competencies locally while also drawing on the broader capabilities of the Group to serve regional customer requirements over time.”

A Strategic Step in Global Expansion

The establishment of the company’s first U.S. manufacturing presence represents far more than a capacity expansion. It reflects Supreme Group’s broader vision of building a globally integrated nonwovens business supported by localized manufacturing, customer collaboration, and innovation-driven growth.

By combining its extensive materials expertise with a strong local presence, the company is positioning itself to serve the evolving needs of North American customers more effectively while strengthening its role in the global nonwovens industry.

As demand for advanced materials continues to grow across automotive, industrial, filtration, and technical textile applications, Supreme Group’s latest investment marks an important step in expanding its international footprint and reinforcing its commitment to delivering high-performance, customer-focused nonwoven solutions worldwide.

Free Training

Source link